TrialESMO open2021

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study).

J A Perez-Fidalgo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.